IL286415A - Monoclonal antibodies for prevention and treatment of herpes simplex viral infections - Google Patents

Monoclonal antibodies for prevention and treatment of herpes simplex viral infections

Info

Publication number
IL286415A
IL286415A IL286415A IL28641521A IL286415A IL 286415 A IL286415 A IL 286415A IL 286415 A IL286415 A IL 286415A IL 28641521 A IL28641521 A IL 28641521A IL 286415 A IL286415 A IL 286415A
Authority
IL
Israel
Prior art keywords
prevention
treatment
monoclonal antibodies
herpes simplex
viral infections
Prior art date
Application number
IL286415A
Other languages
English (en)
Hebrew (he)
Original Assignee
Albert Einstein College Medicine
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Medicine, Univ Duke filed Critical Albert Einstein College Medicine
Publication of IL286415A publication Critical patent/IL286415A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL286415A 2019-03-19 2021-09-14 Monoclonal antibodies for prevention and treatment of herpes simplex viral infections IL286415A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962820495P 2019-03-19 2019-03-19
PCT/US2020/023600 WO2020191181A1 (en) 2019-03-19 2020-03-19 Monoclonal antibodies for prevention and treatment of herpes simplex viral infections

Publications (1)

Publication Number Publication Date
IL286415A true IL286415A (en) 2021-10-31

Family

ID=70285944

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286415A IL286415A (en) 2019-03-19 2021-09-14 Monoclonal antibodies for prevention and treatment of herpes simplex viral infections

Country Status (9)

Country Link
US (1) US12459987B2 (enExample)
EP (1) EP3941524A1 (enExample)
JP (1) JP7835392B2 (enExample)
KR (1) KR20210141948A (enExample)
CN (2) CN113661176B (enExample)
AU (1) AU2020242042A1 (enExample)
CA (1) CA3133862A1 (enExample)
IL (1) IL286415A (enExample)
WO (1) WO2020191181A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805579B (zh) * 2022-06-08 2023-06-06 郑州大学 一种抗人ace2蛋白单克隆抗体、核酸分子及应用
TWI876557B (zh) * 2022-09-30 2025-03-11 臺北醫學大學 用於前列腺癌診斷和早期發病的單株抗體
CN119751660B (zh) * 2024-12-02 2026-04-03 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种猫麻疹病毒特异性单克隆抗体及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
AU1866895A (en) 1994-01-04 1995-08-01 Scripps Research Institute, The Human monoclonal antibodies to herpes simplex virus and methods therefor
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
EP2308895A1 (en) * 2009-10-01 2011-04-13 Universität Duisburg-Essen Anti-HSV antibody
ES2843277T3 (es) 2014-06-26 2021-07-16 Heidelberg Immunotherapeutics Gmbh Aplicación tópica para un anticuerpo anti-VHS
JP2020504105A (ja) 2016-12-19 2020-02-06 グレンマーク・ファーマシューティカルズ・エスエー 新規なｔｎｆｒアゴニストおよびその使用
CN111148832A (zh) 2017-08-30 2020-05-12 Km生物医薬股份公司 抗HSV gB单克隆抗体或其抗原结合片段

Also Published As

Publication number Publication date
WO2020191181A9 (en) 2020-12-10
US12459987B2 (en) 2025-11-04
CN113661176A (zh) 2021-11-16
JP7835392B2 (ja) 2026-03-25
KR20210141948A (ko) 2021-11-23
AU2020242042A1 (en) 2021-09-16
CA3133862A1 (en) 2020-09-24
CN113661176B (zh) 2025-02-18
JP2022525535A (ja) 2022-05-17
CN119899260A (zh) 2025-04-29
EP3941524A1 (en) 2022-01-26
WO2020191181A1 (en) 2020-09-24
US20220162291A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
IL287025A (en) Systems and methods to classify antibodies
IL281277A (en) Preparations and methods for treating viral infections
IL280563A (en) Anti-btn3a antibodies and their use in treating cancer or infectious disorders
EP3380621A4 (en) CONSTRUCTION OF THE VECTOR OF OBLIGATES ONCOLYTIC HERPES SIMPLEX VIRUSES (OHSV) AND CANCER THERAPY CONSTRUCTIONS
IL290792B1 (en) Preparations and methods for treating viral infections
PL3638698T3 (pl) Przeciwciała i fragmenty wiążące antygen anty-TMPRSS2
PH12018502673A1 (en) Anti-zika virus antibodies and methods of use
PL4157272T3 (pl) Remdesiwir do leczenia zakażeń wirusowych
IL284044A (en) Antibodies that neutralize hepatitis b virus and uses thereof
ZA202104357B (en) Monoclonal antibodies against the beta chain region of human trbv9
IL289829A (en) Immunomodulatory antibodies and methods of use thereof
ZA202007649B (en) Virus and antigen purification and conjugation
IL287690A (en) Anti-hvem antibodies and use thereof
IL286473A (en) Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
PT4082570T (pt) Anticorpo anti-ctla-4 e a sua utilização
IL276008A (en) Antibodies that increase factor h activity and their uses
IL286690A (en) Anti-egfrviii antibodies and antigen-binding fragments thereof
HRP20260007T1 (hr) Humanizirano antitijelo protiv il17a i njegova uporaba
KR101882087B1 (ko) 어류 바이러스성 출혈성 패혈증 바이러스에 특이적인 단클론항체 및 이의 용도
WO2020106358A8 (en) Novel anti-zika virus antibodies and uses thereof
IL291546A (en) Anti-kir3dl3 antibodies and uses thereof
IL291280A (en) Anti-cd371 antibodies and uses thereof
EP3677677A4 (en) MONOCLONAL ANTIBODY AGAINST HSV GB OR CORRESPONDING ANTIGEN BINDING FRAGMENT
EP3521308C0 (en) HUMANIZED AND DE-IMMUNE ANTIBODIES
IL283039A (en) Immunogenic compositions for treatment of hepatitis b